The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
about
The Yin and Yang of Toll-like receptors in cancerToll-like Receptors in Ovarian Cancer as Targets for ImmunotherapiesUnderstanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapyNucleic acids and endosomal pattern recognition: how to tell friend from foe?Skin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cellsViral ssRNA induces first trimester trophoblast apoptosis through an inflammatory mechanism.Immunotherapy of Dual-Function Vector with Both Immunostimulatory and B-Cell Lymphoma 2 (Bcl-2)-Silencing Effects on Gastric Carcinoma.Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance.TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFNCombination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumorsSilencing of renal DNaseI in murine lupus nephritis imposes exposure of large chromatin fragments and activation of Toll like receptors and the Clec4e.Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environmentMurine mammary carcinoma cells and CD11c(+) dendritic cells elicit distinct responses to lipopolysaccharide and exhibit differential expression of genes required for TLR4 signalingTopical imiquimod has therapeutic and immunomodulatory effects against intracranial tumorsTargeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide.TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence.The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.Laser-engineered dissolving microneedle arrays for protein delivery: potential for enhanced intradermal vaccination.Negative feedback circuit for toll like receptor-8 activation in human embryonic Kidney 293 using outer membrane vesicle delivered bi-specific siRNA.Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.Insights on the mechanism of action of immunostimulants in relation to their pharmacological potency. The effects of imidazoquinolines on TLR8.Systemic treatment for hereditary cancers: a 2012 update.Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignanciesIs the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinomaUse of anti-cancer drugs, mitocans, to enhance the immune responses against tumors.Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib.IL-12 secretion by Langerhans cells stimulated with Candida skin test reagent is mediated by dectin-1 in some healthy individuals.Multipeptide vaccination in cancer patients.Imiquimod-induced CCR9 Ameliorates murine TNBS ColitisThe TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.TLR7-expressing cells comprise an interfollicular epidermal stem cell population in murine epidermis.Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.Chromatin as a target antigen in human and murine lupus nephritisAdjuvants for enhancing the immunogenicity of whole tumor cell vaccines.Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis?Targeting the tumor microenvironment by immunotherapy: part 2.Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials.Insights into the Relationship between Toll Like Receptors and Gamma Delta T Cell Responses.Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
P2860
Q26851526-E35B363A-0E07-4B21-B49D-5B4739AC44A8Q26861234-BC0D990A-C73C-4BB9-AE05-FB113684B0D0Q27004702-C3DE4F18-918B-4A55-A2EA-4CA174BF27A8Q27022525-202C50BF-8413-45A8-8291-B33CCC75074FQ27323190-872F7EBC-8C16-4742-B79A-D29845FD587DQ33533447-0D94200D-9FB4-43C1-B077-26AF873B8248Q33626347-340CCF2A-4576-4A16-9FEB-FD39C830BD20Q33755300-1DAC6ABD-9367-4A09-8415-B95EB0FA9A1DQ33763210-0C87EFDF-B81C-484A-AB94-D2DA1A81B98BQ33824623-BCDD1752-487B-4419-81B8-33813E01EAE7Q34222085-4CB3F272-9D05-4152-9A21-BBC8D663D240Q34242591-46F08606-CEAE-406D-8958-77271029E2C8Q34253167-3EDCA52E-48A7-4851-9078-6205285AAD6EQ34777706-52660D9E-F704-4804-BB7A-37E30C2C31E0Q34818576-555C2E24-1E8F-4BF7-A6B1-3529DF154640Q34880391-F97C528C-E597-4C6C-82D0-2CA9CD57DB43Q35018021-4C77115A-6A18-45A2-8976-E7A7ADFCDEFDQ35132732-613DB472-8D17-42FF-A751-FD3BDCF9C80EQ35707013-4714CDCD-3188-4DCB-BAF3-0460044F42F7Q36215126-8B943F58-2C4E-4E53-A614-554B20D9B0EEQ36393002-E7275A6F-5137-48F0-A774-B18F498A56DAQ36755366-EDDCF55B-82AC-4506-8045-4859BA526417Q36802795-6E468A40-BB70-4A4B-BAA9-C6BEBC42966AQ36843741-B4A8E586-D593-4C66-AEBE-04BC4E26583FQ36884862-84F551E6-2511-4B28-9E40-E5959177613DQ37308070-DB53A7F0-54E7-4496-AD3B-4EA9C12DA815Q37522371-4248E37C-9189-4DA5-B3F8-F916558B5AD2Q37532916-9B5DCB89-1F3F-4A3D-BB96-7409B05CE65FQ37547268-7F6858DD-A320-4B45-A9F7-04878DFA66C2Q37616805-8516B5AB-24B9-435E-BCE4-95E6B4D7FCC0Q37728656-D2B1FD55-7B2A-461B-934E-BE7B3286F0B1Q37733130-920E3DDC-D037-418D-93EB-9BE70726E037Q37868974-D5F5B489-F39F-43C6-BFB3-2F562E8A40D4Q37872038-D1F2CA45-3A94-4FF8-9536-628CCB2B87B8Q37873932-3401CCF9-2756-439C-8233-76C4D1CFA24EQ37952071-B72A78D7-1E6F-4C18-9DEF-F7195EE923E1Q37952796-CC701328-3F3B-482C-9359-3D1C5D693854Q38059516-9D827060-DB47-4348-96EA-5B7DC57980D7Q38240851-FD512EAE-5E3B-4AF2-8949-0AA2315052D1Q38261273-F550561E-1FFD-47CE-A576-BD2D35766158
P2860
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
@en
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
@nl
type
label
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
@en
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
@nl
prefLabel
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
@en
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
@nl
P2093
P1433
P1476
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
@en
P2093
Evelien L J M Smits
Peter Ponsaerts
Viggo F I Van Tendeloo
P304
P356
10.1634/THEONCOLOGIST.2008-0097
P50
P577
2008-08-13T00:00:00Z